Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Clinical trial NCT05290155 · COMPLETED

Trial details

NCT number: NCT05290155
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

T Lymphoblastic Leukemia/Lymphoma T-cell Acute Lymphoblastic Leukemia Peripheral T Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Anaplastic Large Cell Lymphoma

Start date: 2022-05-04
Primary completion: 2024-08-01
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.